昂丹司琼

Ondansetron is a 5-HT3 receptor antagonist with antiemetic activity. It is used in the control and prevention of nausea and vomiting. Administered intravenously, intramuscularly, orally or rectally in one or two doses per day.

Since the last update, we have not found published data on its excretion in breastmilk.

Its high volume of distribution and short half-life make it unlikely that it will be excreted in breast milk in significant quantities.

* A computer model based on pharmacokinetic data predicts a clinically insignificant exposure to the infant (theoretical dose 0.005 mg/kg) at a relative dose of 3%. ^{(Job 2022)}

No problems have been reported in infants of mothers treated with ondansetron. ^{(Zhao 2020, Job 2022)}

Administration of ondansetron after caesarean section does not affect a positive start to breastfeeing ^{(Zhao 2020, Jelting 2017, Uerpairojkit 2017)}, or the health of the newborn. ^{(Nallam 2017, Elkomy 2015)}

Its use is safe in children between 1 and 24 months. ^{(Khalil 2005).}

Onsdansetron does not affect prolactin production. ^{(Lisson 1994)}

It is considered by experts and prestigious medical associations to be safe, probably compatible or of choice in breastfeeding. ^{(Hale, LactMed, Reece-Stremtan 2017, Rowe 2016, Briggs 2015, Mahadevan 2006)}